0

A Raf Kinase Inhibitor Demonstrates Antiviral Activities Both in Vitro and in Vivo Against Different Genotypes of Virulent Newcastle Disease Virus

Renfu Yin, Xinxin Liu, Pingze Zhang, Yanyu Chen, Guangyao Xie, Lili Ai, Cong Xue, Jing Qian, Yuhai Bi, Jianjun Chen, Yuzhang Sun, Tobias Stoeger, Zhuang Ding

Antiviral Res. 2016 Sep;133:140-4.

PMID: 27498149

Abstract:

Newcastle disease (ND) is still one of the major plagues of birds worldwide. Combat actions are limited to vaccines, highlighting the urgent need for new and amply available antiviral drugs. Previous results have shown that Newcastle disease virus (NDV) downregulates the intracellular Raf kinase inhibitor protein (RKIP) expression for efficient replication, suggesting that this molecular may be a suitable target for antiviral intervention. In the present work, we investigated whether or not the Raf kinase inhibitor V (RKIV), which functions in the same way as RKIP by targeting the intracellular Raf kinase, is able to suppress the propagation of enzootic virulent NDV in vitro and in vivo. In vitro antiviral activity of RKIV was assessed by cell-based assay, and in vivo activity was determined in the chicken model. Our results clearly showed that RKIV treatment protected the cells from NDV-induced CPE with the effective concentrations on nM level, and inhibited virus replication in the lungs of infected chickens in a dose-dependent manner and protected chickens from the lethal infection by NDV. Thus, we conclude that the Raf kinase inhibitor compound RKIV, by inhibiting the host cellular target Raf kinase, might be very promising as a new class of antivirals against the enzootic virulent NDV infection.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP331444407 Raf Kinase Inhibitor VI - CAS 331444-40-7 Raf Kinase Inhibitor VI - CAS 331444-40-7 331444-40-7 Price
AP918505847 Raf Kinase Inhibitor V - CAS 918505-84-7 Raf Kinase Inhibitor V - CAS 918505-84-7 918505-84-7 Price
qrcode